The Use of Biologics in Patients with Inflammatory Bowel Disease and Primary Sclerosing Cholangitis.

Curr Hepatol Rep · 2019 · PMC6445403 · PMID 31008013

Europe PMC DOI

hedged sentence

0.0520

closest p · 1.0× alpha

0.0520

boldest claim

The sentences

did not reach statistical significancep = 0.052so close (0.05 < p ≤ 0.1)

Whilst there was no difference in mean ALP over time for patients on IFX, there was a statistically significant drop in mean ALP for those on ADA from 249 U/L (SD 158) at baseline to 179 U/L (SD 126) at 6–8 months ( p = 0.003), and a numerical further drop at 12–14 months to 171 U/L (SD 140) which did not reach statistical significance ( p = 0.052).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.